Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 15;10:8056. doi: 10.1038/s41598-020-64841-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Percentage and count of ARG1-expressing cells in different immunophenotype tumor-infiltrating MDSCs. (a) Flow cytometry chart of ARG1-expressing MDSCs in gastric cancer tissue (GC-T) and paracancerous tissues (PC-T). Cells were first gated based on the expression of HLA-DR and ARG1. Subsequently, the HLA-DR ^-/low ARG1⁺ population were gated based on the expression of CD11b and CD33. The HLA-DR^-CD33⁺CD11b^-, HLA-DR^-CD33⁺CD11b⁺ and HLA-DR^-CD33^-CD11b^- population were gated based on the expression of CD14 and CD15. An isotype control was also run (Supplementary Fig. 2). (b) The percentage and count of ARG1-expressing HLA-DR^- mononuclear cells in GC-T or PC-T. (c) Gated on HLA-DR^-CD33⁺, the percentage and count of ARG1-expressing CD11b⁺ or CD11b^- MDSC subsets in GC-T or PC-T. (d) Gated on HLA-DR^-CD33^-, the percentage and count of ARG1-expressing CD11b⁺ or CD11b^- MDSC subsets in GC-T or PC-T. (e) Gated on HLA-DR^-CD33⁺CD11b⁺, the percentage and count of ARG1-expressing CD14⁺CD15^- or CD14^-CD15^-MDSC subsets in GC-T or PC-T. (f) Gated on HLA-DR^-CD33⁺CD11b^-, the percentage and count of ARG1-expressing CD14⁺CD15^- or CD14^-CD15^-MDSC subsets in GC-T or PC-T. (g) Gated on HLA-DR^-CD33^-CD11b^-, The percentage and count of ARG1-expressing CD14⁺CD15^- or CD14^-CD15^-MDSC subsets in GC-T or PC-T. Values were mean ± SEM (n = 6), **p < 0.01. Paired /Wilcoxon matched-pairs signed rank test or unpaired/Mann–Whitney tests.